U.S. markets closed

iTeos Therapeutics, Inc. (ITOS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
28.75+0.04 (+0.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close28.71
Bid20.00 x 1300
Ask29.75 x 1000
Day's Range28.37 - 29.11
52 Week Range17.43 - 47.61
Avg. Volume325,020
Market Cap1.012B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.05
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iTeos Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/13/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Simply Wall St.

    iTeos Therapeutics, Inc. (NASDAQ:ITOS) Is About To Turn The Corner

    iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) is possibly approaching a major achievement in its business, so we would like...

  • GlobeNewswire

    iTeos Therapeutics to Participate in Upcoming September Investor Conferences

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company management will participate in five upcoming virtual investor conferences in September: KBC Securities Life Sciences ConferenceFormat: Management one-on-onesDate: September 7, 2021 W

  • GlobeNewswire

    iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update

    Announced co-development and co-commercialization collaboration with GSK for anti-TIGIT monoclonal antibody EOS-448 (GSK’859); $625MM upfront payment in addition to $1.45B in potential milestones, 40/60 cost-sharing of global development, 50/50 profit share in the US, and royalty payments on ex-US sales Presented initial clinical data for EOS-448 at AACR 2021 demonstrating target engagement, promising early monotherapy anti-cancer activity and tolerability at all dose levels Updated data from Ph